Receptos +36.7% AH; RPC1063 hits primary endpoint


Receptos' (RCPT) RPC1063 multiple sclerosis drug met its primary endpoint (reduction in MRI brain lesion activity) during Phase 2 trials.

The company adds its ongoing Phase 3 trial "has been designed to confirm and extend [Phase 2] results." Phase 2 results for the use of RPC1063 in treating ulcerative colitis are expected in Q4.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs